Processa Pharmaceuticals, Inc. Quarterly Operating Income (Loss) in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Processa Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2017 to Q3 2024.
  • Processa Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$3.42M, a 58% decline year-over-year.
  • Processa Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$11.8M, a 46.6% increase year-over-year.
  • Processa Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$11.5M, a 58.4% increase from 2022.
  • Processa Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$27.5M, a 127% decline from 2021.
  • Processa Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$12.1M, a 19.8% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$11.8M -$3.42M -$1.26M -58% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-30
Q2 2024 -$10.5M -$3.08M -$368K -13.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 -$10.2M -$2.81M +$1.3M +31.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-10
Q4 2023 -$11.5M -$2.47M +$10.6M +81.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-29
Q3 2023 -$22.1M -$2.17M +$3.89M +64.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-30
Q2 2023 -$25.9M -$2.71M +$2.46M +47.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$28.4M -$4.11M -$877K -27.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-10
Q4 2022 -$27.5M -$13.1M -$9.7M -288% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-29
Q3 2022 -$17.8M -$6.06M -$2.95M -94.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$14.9M -$5.17M -$1.71M -49.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$13.2M -$3.23M -$1.04M -47.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$12.1M -$3.37M +$7.02M +67.6% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 -$19.2M -$3.11M -$156K -5.27% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$19M -$3.46M -$2.66M -331% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$16.3M -$2.19M -$1.21M -122% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$15.1M -$10.4M -$9.48M -1040% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-30
Q3 2020 -$5.66M -$2.96M -$1.95M -194% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$3.7M -$802K +$335K +29.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$4.04M -$986K -$104K -11.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 -$3.94M -$912K -$170K -22.9% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-25
Q3 2019 -$3.77M -$1M +$59K +5.55% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$3.82M -$1.14M +$291K +20.4% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 -$4.12M -$883K +$409K +31.7% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q4 2018 -$4.52M -$742K -$167K -29% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-06
Q3 2018 -$4.36M -$1.06M -$350K -49.1% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$4.01M -$1.43M -$1.15M -409% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 -$2.86M -$1.29M -$1.06M -452% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-14
Q4 2017 -$1.8M -$575K Oct 1, 2017 Dec 31, 2017 10-K/A 2019-04-08
Q3 2017 -$713K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-14
Q2 2017 -$280K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
Q1 2017 -$234K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.